NCT06898398 TACE Combined Surgery for the Resectable Huge HCC
| NCT ID | NCT06898398 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Sun Yat-sen University |
| Condition | Hepatocellular Carcinoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 326 participants |
| Start Date | 2025-01-01 |
| Primary Completion | 2025-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 326 participants in total. It began in 2025-01-01 with a primary completion date of 2025-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Huge hepatocellular carcinoma (HCC) is defined as a tumor with a maximum diameter greater than 10 cm. With advancements in surgical techniques, hepatectomy can be performed safely in some patients with huge HCC without vascular invasion or distant metastasis and with preserved liver function. The high risk of recurrence after surgery is another challenge for surgeons. Neoadjuvant TACE has been shown to improve the clinical outcomes of patients with HCC, especially those with a high risk of recurrence, such as those with multinodular tumors, large tumors, and tumor thrombus. The present multicenter study aimed to evaluate the efficacy of neoadjuvant TACE in patients with huge HCC who underwent liver resection.
Eligibility Criteria
Inclusion Criteria: 1. clinical or pathological diagnosis of primary HCC; 2. tumor diameter \> 10 cm on images before inclusion; 3. age 18 to 75 years; 4. no macrovascular invasion or extrahepatic metastasis; 5. liver resection with complete removal of the tumor and adequate remnant liver volume; 6. albumin-bilirubin (ALBI) grade I and II; 7. Eastern Cooperative Oncology Group performance status (ECOG) score of 0-1; 8. hemoglobin level ≥ 8.5 g/dL, total bilirubin level ≤ 30 mmol/L, alanine transaminase (ALT) and aspartate aminotransferase (AST) levels ≤ 5 × upper limit of normal, serum creatinine level ≤ 1.5 × upper limit of normal; 9. prothrombin time ≤ 18 s or international normalized ratio \< 1.7. Exclusion Criteria: 1. HCC with macrovascular invasion or extrahepatic metastasis; 2. tumor with a maximum diameter ≤ 10 cm on images before inclusion; 3. recurrent HCC; 4. serious medical comorbidities; 5. portal hypertension, including presence of either esophageal varices or splenomegaly with a platelet count less than 109/L; 6. cardiac ventricular arrhythmias requiring anti-arrhythmic therapy; 7. incomplete data or lost to follow-up within three months.
Contact & Investigator
Feng Duan, MD
PRINCIPAL INVESTIGATOR
Chinese PLA General Hospital
Frequently Asked Questions
Who can join the NCT06898398 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Hepatocellular Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06898398 currently recruiting?
Yes, NCT06898398 is actively recruiting participants. Contact the research team at zhouqun988509@163.com for enrollment information.
Where is the NCT06898398 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT06898398 clinical trial?
NCT06898398 is sponsored by Sun Yat-sen University. The principal investigator is Feng Duan, MD at Chinese PLA General Hospital. The trial plans to enroll 326 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.